Member Info for AndytheMKDon

Money for jam..

Hey buddy I'm not looking to prove anybody wrong, all I'm suggesting is the new initiative from CRUK has to be synergistic with work they did on Chk1 and the on-going activities of Sierra. As I mentioned CRUK own 73% of Chk1 so will be fully aware of progress hence imho their desire to commence their own developments along a similar route as Sierra utilising combo treatments to degrade cancer cells beyond recovery. gl fella, et-al. Andy. :+)

Are still the majority owner of Chk1 so off course these reports relate to SAR and Sierra. Could be CRUK are about to take Tyk2 and progress it to the clinic the same as they did for Chk1 after all they will have to find something for the three hundred new recruits to work upon.. !!

https://news.sky.com/story/breakthrough-cancer-treatments-to-target-drugs-resistance-11721159

Sky news are reporting that new cancer treatments, sounding very much like ours, as one of their main headlines.

They refer to combination treatments which sound very much like the current Sierra trials and maybe the combo with PARP inhibitors they are about to commence.

All you need to do now Timbo, if they are talking about us, is get yourself on the local news and identify SAR as a key player in these novel new treatments. simples.. :+)

Hello Aber. No, but all indications are that this is an effective treatment otherwise they would be downplaying the results which they are about to publish. As more information is published building expectations we should be more confident of good outcomes from trials to date. Gl. Andy.

SRA737:
•SRA737 is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer across multiple indications. The SRA737-01 trial is intended to evaluate SRA737's potential to induce synthetic lethality as monotherapy, while the SRA737-02 trial is intended to evaluate the combination of SRA737 potentiated by non-cytotoxic LDG. Sierra expects to report preliminary data from both trials at the 2019 ASCO Annual Meeting being held in early June 2019 .
•In addition, Sierra has designed clinical trials and has conducted preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including poly ADP-ribose polymerase (PARP) inhibitors, as well as with immuno-oncology therapeutics, that could potentially guide the next planned wave of clinical development for this asset. Sierra has an agreement with Janssen Research & Development, LLC (Janssen), under which Janssen has agreed to supply the PARP inhibitor niraparib, facilitating the potential initiation of a PARP inhibitor combination trial with SRA737 for the treatment of prostate cancer. Sierra is currently evaluating the optimal timing to commence this trial within the context of its recently expanded portfolio.
•During the first quarter of 2019, Sierra reported preclinical data for SRA737+LDG, in combination with immunotherapy, in a late-breaking oral presentation at the AACR Annual Meeting 2019. In the study, SRA737+LDG demonstrated significant anti-tumor activity when combined with anti-PD-L1 in a mouse model of SCLC, resulting in durable tumor regressions. These findings provide a mechanistic basis for the growing body of evidence demonstrating a synergistic interplay between replication stress and anti-tumor immune responses and afford a compelling rationale for evaluating SRA737+LDG with immunotherapy in the clinic.

Kuenzel knows what he is and couldn't give a bugger so long as the salary lands every month.

Kuenzel, Landau and co were a group of west Aussie shysters based in Perth who figured out how to milk the aim market fifteen years ago unfettered by the toothless FCA who know what goes on but chooses to look the other way.

Money can be made if you know when to get into their company's and when to get out.

Got this one wrong!! However this will turn as they can't wring out the sponge much longer before tipping the seesaw the other way.

They probably don't own the shares, when people take a short position they theoretically borrow the shares, so taking they "borrowed" shares at 6p back in Jan they will pay for them at a current price of 3p for a nice 100% profit. My feeling is this stock has been shorted all the way down from 20p on the constant promise of jam tomorrow which has been the form of Geo for years.. Sell the sizzle and never deliver a sausage. Having said this having now declared the holding from a position held back in January !!! they are now most likely looking to close it out to start banging the tambourine again or should I say begging bowl.. Struthers and O'Brien my be legit but Kuenzel is a freeloader who dates back to Pete Landau's notorious aim antics which are well documented if you care to Google him.

You've all missed the point, the TR1 states more than 3% of the stock is now on a spread bet platform i.e. being shorted no doubt. My take is the twots running this company have shorted the stock knowing there would be no news on progress. And yes I am invested. This company needs investigating, all the horlicks they came out with years ago about gold in Austria only to never hear of it again, and now the same repeat side show in Georgia whilst they continue to draw eye watering salaries funded by ever repeating placing's. Dodgy bastards.!!

We know with SAR that most rises are driven by volume, also most of the volume today are buys. Looks to me as though the pending news flow could well be giving us a lift, we just need some good news to trigger a re-rate imo.
Chk1 one progress?? Tyk 2 license agreement?? Milestone payment?? All three?? Lets home the long termers get something to put a smile on our faces.. gl fella..

Almost 12M shares traded today and looks like a bit of pressure coming on the ask. :+) GLA. Andy.

Not all trades go through london stock exchange they can go through other platforms or direct market access especially larger trades.

But it's Wetherspoons.. ;+))

The last time we had a ten out of ten mice rns it took two days for the sp to react. ;@) having said that it does seem a bit like groundhog day i was expecting more if im honest
.

Refreshing to see a polite and informed bulletin board which we have here in SAR, a rare exception to the dross and antics we see on many other bb's.. Meanwhile back at the share price I see the mm's have finally come out to play.. :+) GLA.

Hi. I get your point but lets put it this way, if you were about to get married would you still want your future bride out there on dating sites?? löl.. GL.

Hi.. You're spot on with the business model of SAR hence my earlier post suggesting Sierra will get bought and with it Chk1. Regarding Tyk2 value, this is where I bow to the greater knowledge of Toth2, he suggests that given its wide variety of applications it could be worth billions. So in summary are SAR a T/O target ?? I guess they must be as the products develop, as it is surely cheaper to buy them now at a modest price than to pay a multiple should any of their products prove commercial. GL.

Hey both.. If we are in advanced talks with an interested party for Tyk2 or SAR as a whole then an NDA will be in place, hence the silence. GL.. Andy.

Sierra will be bought out, that is their business model, and with it Chk1 will be acquired by whoever. At which point I believe ours and CRUK's milestones would be fully paid up and we would then receive royalties on an on-going basis should commerciality result. With all the current movement in the biotech sphere something has to give sooner or later.